Meta-analysis of insulin aspart versus regular human insulin used in a basal–bolus regimen for the treatment of diabetes mellitus

The objective of the current study was to compare the efficacy of two different insulin formulations, insulin aspart (IAsp) and regular human insulin (RHI), for prandial insulin coverage with neutral protamine Hagedorn (NPH) insulin as basal insulin using a meta‐analysis approach. The primary endpoint was change in A1c over time. Secondary endpoints included incidence of hypoglycemia and postprandial glycemic control.

[1]  A. Lindholm,et al.  Insulin aspart vs. human insulin in the management of long‐term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[2]  S. Mudaliar,et al.  Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. , 1999, Diabetes care.

[3]  A. Lindholm,et al.  Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. , 1999, Diabetes care.

[4]  C. Semsarian,et al.  Sudden death in type 1 diabetes: the mystery of the 'dead in bed' syndrome. , 2010, International journal of cardiology.

[5]  Warszawski Uniwersytet Medyczny,et al.  Diabetes care , 2019, Health at a Glance.

[6]  K. Usadel,et al.  Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes. , 2006, Diabetes research and clinical practice.

[7]  D. Sackett,et al.  Cochrane Collaboration , 1994, BMJ.

[8]  T. Christensen,et al.  Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey , 2012, Journal of medical economics.

[9]  B. Frier,et al.  Frequency of Severe Hypoglycemia in Patients With Type I Diabetes With Impaired Awareness of Hypoglycemia , 1994, Diabetes Care.

[10]  A. Lal,et al.  Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis , 2009, Canadian Medical Association Journal.

[11]  Stephen Senn,et al.  Statistical Issues in Drug Development , 1997 .

[12]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[13]  T R Pieber,et al.  Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. , 2006, The Cochrane database of systematic reviews.

[14]  R. Heine,et al.  A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[15]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[16]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[17]  Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. , 1991, The American journal of medicine.

[18]  M. Marre,et al.  Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. , 2001, Diabetes research and clinical practice.

[19]  N. Marchionni,et al.  Short‐acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta‐analysis , 2009, Diabetes, obesity & metabolism.

[20]  Xiaomin Liu,et al.  [Postprandial glycemic control using insulin aspart with NPH in inadequately controlled diabetics]. , 2009, Zhonghua yi xue za zhi.

[21]  C D Naylor,et al.  Meta-analysis of controlled clinical trials. , 1989, The Journal of rheumatology.

[22]  S G Thompson,et al.  Controversies in meta-analysis: the case of the trials of serum cholesterol reduction , 1993, Statistical methods in medical research.

[23]  L. Wolff,et al.  Relationship between lactate dehydrogenase and myeloperoxidase levels in human gingival crevicular fluid and clinical and microbial measurements. , 1988, Journal of clinical periodontology.

[24]  Lawrence A Leiter,et al.  Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. , 2000, Diabetes care.

[25]  P. Home,et al.  Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers , 1999, European Journal of Clinical Pharmacology.

[26]  C. Emery,et al.  Frequency of biochemical hypoglycaemia in adults with Type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[27]  C. Fidler,et al.  Hypoglycemia: An overview of fear of hypoglycemia, quality-of-life, and impact on costs , 2011, Journal of medical economics.

[28]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.

[29]  P. Home,et al.  The Effect of the Insulin Analog Lispro on Nighttime Blood Glucose Control in Type 1 Diabetic Patients , 1998, Diabetes Care.

[30]  D. Cucinotta,et al.  Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double‐blind and cross‐over trial , 2005, Diabetic medicine : a journal of the British Diabetic Association.